Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1

Conditions

Lung Neoplasms 22Leukemia, Myeloid, Acute 21Breast Neoplasms 19Neoplasm Metastasis 16Pancreatic Neoplasms 15Multiple Myeloma 14Prostatic Neoplasms 12Melanoma 12Lymphoma 11Colorectal Neoplasms 11Carcinoma, Renal Cell 11Carcinoma, Non-Small-Cell Lung 11Burkitt Lymphoma 10Triple Negative Breast Neoplasms 9Urinary Bladder Neoplasms 8Squamous Cell Carcinoma of Head and Neck 8Ovarian Neoplasms 8Myelodysplastic Syndromes 8Mouth Neoplasms 8Glioma 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Oropharyngeal Neoplasms 7Leukemia, Lymphocytic, Chronic, B-Cell 7Laryngeal Neoplasms 7Fallopian Tube Neoplasms 7Carcinoma, Hepatocellular 7Carcinoma 7Sarcoma 6Nasopharyngeal Carcinoma 6Endometrial Neoplasms 6

Interventions

Specimen Handling 2Magnetic Resonance Spectroscopy 2sargramostim 1montanide ISA 51 1incomplete Freund's adjuvant 1cabozantinib 1belzutifan 1X-Rays 1Temozolomide 1Phantoms, Imaging 1Methods 1Colony-Stimulating Factors 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Adenoma, Islet Cell × Specimen Handling × 30 days × Clear all
NCT03375320 2026-06-03

Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

National Cancer Institute (NCI)

Phase 3 Active not recruiting
298 enrolled 14 charts 1 FDA
EndocrineGastrointestinalNET

Non functioning pancreatic endocrine tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

NCT06202066 2026-05-28

Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas

Roswell Park Cancer Institute

Phase 2 Recruiting
60 enrolled

Adenoma, Islet Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡